Upper Gastrointestinal Cancer
Conditions
Brief summary
The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab.
Interventions
DRUGNivolumab
As per product label
Sponsors
Bristol-Myers Squibb
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Enrolled in the Bristol-Myers Squibb GastroEsophageal Opdivo in non-Resectable, advanced or metastatic Adenocarcinoma Patient Support Program (GEORgiA PsP) in Canada * Have consented to the use of their de-identified data generated from information collected during the course of the GEORgiA PsP
Exclusion criteria
* Aged \<18 years * HER2 positive status * Untreated brain metastases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Particpant sociodemographics | Baseline |
| Participant Eastern Cooperative Oncology Group (ECOG) score | Baseline |
| Participant HER2 status | Baseline |
| Participant comorbidities | Baseline |
| Participant tumour location | Baseline |
| Participant treatment history | Baseline |
Secondary
| Measure | Time frame |
|---|---|
| Reason for participant discharge | Up to 75 weeks |
| Initial nivolumab dosage prescribed to participants | Index date |
| Management of participant adverse events (AEs) | Up to 75 weeks |
| Participant adverse events (AEs) | Up to 75 weeks |
| Number of nivolumab treatments received by participants | Up to 75 weeks |
| Planned combination chemotherapy treatment | Index date |
| Nivolumab treatment initiation date | Index date |
| Nivolumab dosage modification | Up to 75 weeks |
| Participant treatment duration | Up to 75 weeks |
Countries
Canada
Outcome results
None listed